InMode (NASDAQ:INMD - Get Free Report) had its price target upped by analysts at Barclays from $26.00 to $29.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the healthcare company's stock. Barclays's price target would suggest a potential upside of 60.75% from the company's current price.
Other research analysts have also recently issued research reports about the stock. BTIG Research assumed coverage on shares of InMode in a research note on Thursday, October 17th. They issued a "buy" rating and a $25.00 target price for the company. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $23.00.
Get Our Latest Research Report on INMD
InMode Price Performance
Shares of INMD traded down $0.21 during mid-day trading on Wednesday, reaching $18.04. The company had a trading volume of 1,220,008 shares, compared to its average volume of 866,573. The company's 50-day moving average is $17.36 and its 200-day moving average is $17.21. InMode has a twelve month low of $14.87 and a twelve month high of $26.80. The company has a market capitalization of $1.25 billion, a P/E ratio of 7.68 and a beta of 2.13.
Hedge Funds Weigh In On InMode
Several hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its holdings in InMode by 314.7% during the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company's stock worth $60,000 after acquiring an additional 2,694 shares in the last quarter. Quarry LP grew its position in shares of InMode by 154.3% in the 3rd quarter. Quarry LP now owns 3,781 shares of the healthcare company's stock valued at $64,000 after acquiring an additional 2,294 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of InMode in the fourth quarter valued at approximately $87,000. National Bank of Canada FI grew its stake in InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock valued at $169,000 after buying an additional 579 shares during the last quarter. Finally, GW Henssler & Associates Ltd. acquired a new stake in InMode during the 3rd quarter worth approximately $177,000. Institutional investors and hedge funds own 68.04% of the company's stock.
About InMode
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Read More
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
